Is MRNA or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Scholar Rock N/A -160.19% -87.18%

Does the media favor MRNA or SRRK?

In the previous week, Moderna had 103 more articles in the media than Scholar Rock. MarketBeat recorded 113 mentions for Moderna and 10 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.44 beat Moderna's score of 0.38 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 46 Very Positive mention(s) 16 Positive mention(s) 14 Neutral mention(s) 18 Negative mention(s) 14 Very Negative mention(s) Neutral Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, INCY or SRRK?

Incyte has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 5.04 $1.29B $7.85 16.28 Scholar Rock N/A N/A -$377.94M -$3.45 N/A

Is INCY or SRRK more profitable?

Incyte has a net margin of 27.71% compared to Scholar Rock's net margin of 0.00%. Incyte's return on equity of 29.93% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% Scholar Rock N/A -160.19% -87.18%

Does the media refer more to INCY or SRRK?

In the previous week, Incyte had 17 more articles in the media than Scholar Rock. MarketBeat recorded 27 mentions for Incyte and 10 mentions for Scholar Rock. Incyte's average media sentiment score of 1.11 beat Scholar Rock's score of 0.44 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 18 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BNTX or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Scholar Rock N/A -160.19% -87.18%

Does the media favor BNTX or SRRK?

In the previous week, BioNTech had 10 more articles in the media than Scholar Rock. MarketBeat recorded 20 mentions for BioNTech and 10 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.44 beat BioNTech's score of 0.09 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Neutral Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer UTHR or SRRK?

In the previous week, United Therapeutics had 25 more articles in the media than Scholar Rock. MarketBeat recorded 35 mentions for United Therapeutics and 10 mentions for Scholar Rock. United Therapeutics' average media sentiment score of 1.13 beat Scholar Rock's score of 0.44 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 26 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GMAB or SRRK more profitable?

Genmab A/S has a net margin of 19.08% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 19.08% 14.89% 7.73% Scholar Rock N/A -160.19% -87.18%

Does the media prefer GMAB or SRRK?

In the previous week, Scholar Rock had 9 more articles in the media than Genmab A/S. MarketBeat recorded 10 mentions for Scholar Rock and 1 mentions for Genmab A/S. Scholar Rock's average media sentiment score of 0.44 beat Genmab A/S's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scholar Rock 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Scholar Rock (SRRK) Competitors

$56.50 +1.25 (+2.26%)

As of 08/21/2026 04:00 PM Eastern

Compare

SRRK vs. MRNA, INCY, BNTX, UTHR, and GMAB

Should you buy Scholar Rock stock or one of its competitors? Scholar Rock's main competitors and comparable companies include Moderna (MRNA), Incyte (INCY), BioNTech (BNTX), United Therapeutics (UTHR), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Scholar Rock compare to Moderna?

Moderna (NASDAQ:MRNA) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Scholar Rock has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Scholar Rock	N/A	-160.19%	-87.18%

Scholar Rock has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	29.79	-$2.82B	-$7.99	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

75.3% of Moderna shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 10.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Moderna currently has a consensus target price of $69.50, indicating a potential downside of 52.09%. Scholar Rock has a consensus target price of $58.77, indicating a potential upside of 4.02%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

In the previous week, Moderna had 103 more articles in the media than Scholar Rock. MarketBeat recorded 113 mentions for Moderna and 10 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.44 beat Moderna's score of 0.38 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	46 Very Positive mention(s)	16 Positive mention(s)	14 Neutral mention(s)	18 Negative mention(s)	14 Very Negative mention(s)	Neutral
Scholar Rock	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moderna has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Summary

Scholar Rock beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Incyte?

Incyte (NASDAQ:INCY) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Incyte has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Incyte has a net margin of 27.71% compared to Scholar Rock's net margin of 0.00%. Incyte's return on equity of 29.93% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Scholar Rock	N/A	-160.19%	-87.18%

Incyte has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	5.04	$1.29B	$7.85	16.28
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Incyte presently has a consensus target price of $123.10, suggesting a potential downside of 3.69%. Scholar Rock has a consensus target price of $58.77, suggesting a potential upside of 4.02%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts clearly believe Scholar Rock is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.48
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

97.0% of Incyte shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Incyte had 17 more articles in the media than Scholar Rock. MarketBeat recorded 27 mentions for Incyte and 10 mentions for Scholar Rock. Incyte's average media sentiment score of 1.11 beat Scholar Rock's score of 0.44 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	18 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Incyte beats Scholar Rock on 13 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Scholar Rock has lower revenue, but higher earnings than BioNTech. Scholar Rock is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	9.08	-$1.29B	-$7.83	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

BioNTech presently has a consensus target price of $127.81, indicating a potential upside of 9.64%. Scholar Rock has a consensus target price of $58.77, indicating a potential upside of 4.02%. Given BioNTech's higher possible upside, equities research analysts clearly believe BioNTech is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

Scholar Rock has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Scholar Rock	N/A	-160.19%	-87.18%

In the previous week, BioNTech had 10 more articles in the media than Scholar Rock. MarketBeat recorded 20 mentions for BioNTech and 10 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.44 beat BioNTech's score of 0.09 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Neutral
Scholar Rock	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioNTech has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Summary

BioNTech beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

United Therapeutics presently has a consensus target price of $646.00, indicating a potential upside of 25.90%. Scholar Rock has a consensus target price of $58.77, indicating a potential upside of 4.02%. Given United Therapeutics' higher possible upside, research analysts clearly believe United Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

In the previous week, United Therapeutics had 25 more articles in the media than Scholar Rock. MarketBeat recorded 35 mentions for United Therapeutics and 10 mentions for Scholar Rock. United Therapeutics' average media sentiment score of 1.13 beat Scholar Rock's score of 0.44 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	26 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

United Therapeutics has a net margin of 41.56% compared to Scholar Rock's net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Scholar Rock	N/A	-160.19%	-87.18%

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 10.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

United Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

United Therapeutics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.15B	6.98	$1.33B	$27.95	18.36
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Summary

United Therapeutics beats Scholar Rock on 11 of the 15 factors compared between the two stocks.

How does Scholar Rock compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Genmab A/S has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.61	$963M	$1.27	26.34
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

In the previous week, Scholar Rock had 9 more articles in the media than Genmab A/S. MarketBeat recorded 10 mentions for Scholar Rock and 1 mentions for Genmab A/S. Scholar Rock's average media sentiment score of 0.44 beat Genmab A/S's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scholar Rock	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S has a net margin of 19.08% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Scholar Rock	N/A	-160.19%	-87.18%

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Genmab A/S presently has a consensus price target of $39.50, suggesting a potential upside of 18.09%. Scholar Rock has a consensus price target of $58.77, suggesting a potential upside of 4.02%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	3.13

Summary

Genmab A/S beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

Get Scholar Rock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRRK vs. The Competition

Export

Metric	Scholar Rock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.88B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-16.38	11.62	272.60	24.24
Price / Sales	N/A	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	27.16	16.80	13.05	6.20
Net Income	-$377.94M	-$12.50M	$3.47B	$348.59M
7 Day Performance	7.58%	3.29%	2.09%	0.08%
1 Month Performance	14.19%	8.23%	6.64%	3.88%
1 Year Performance	59.20%	55.05%	25.02%	16.98%

Scholar Rock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRRK Scholar Rock	1.656 of 5 stars	$56.50 +2.3%	$58.77 +4.0%	+59.2%	$6.88B	N/A	N/A	140	News Coverage Analyst Forecast
MRNA Moderna	1.6484 of 5 stars	$64.46 +1.8%	$42.13 -34.6%	+434.9%	$25.28B	$1.94B	N/A	4,700	Trending News Analyst Upgrade Options Volume
INCY Incyte	3.5888 of 5 stars	$123.50 +2.8%	$121.65 -1.5%	+50.3%	$24.36B	$5.14B	15.73	2,844	News Coverage Positive News Analyst Forecast Insider Trade
BNTX BioNTech	2.479 of 5 stars	$91.60 -1.6%	$127.81 +39.5%	+5.1%	$23.54B	$3.25B	N/A	7,807	Trending News Options Volume
UTHR United Therapeutics	4.215 of 5 stars	$508.48 +1.8%	$646.00 +27.0%	+64.3%	$21.43B	$3.18B	18.19	1,400	News Coverage Positive News Insider Trade Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRRK) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scholar Rock (SRRK) Competitors

SRRK vs. MRNA, INCY, BNTX, UTHR, and GMAB

How does Scholar Rock compare to Moderna?

Summary

How does Scholar Rock compare to Incyte?

Summary

How does Scholar Rock compare to BioNTech?

Summary

How does Scholar Rock compare to United Therapeutics?

Summary

How does Scholar Rock compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scholar Rock (SRRK) Competitors

SRRK vs. MRNA, INCY, BNTX, UTHR, and GMAB

How does Scholar Rock compare to Moderna?

Is MRNA or SRRK more profitable?

Which has stronger valuation & earnings, MRNA or SRRK?

Do institutionals & insiders believe in MRNA or SRRK?

Do analysts recommend MRNA or SRRK?

Does the media favor MRNA or SRRK?

Which has more volatility and risk, MRNA or SRRK?

Summary

How does Scholar Rock compare to Incyte?

Which has more risk and volatility, INCY or SRRK?

Is INCY or SRRK more profitable?

Which has preferable earnings and valuation, INCY or SRRK?

Do analysts prefer INCY or SRRK?

Do institutionals & insiders hold more shares of INCY or SRRK?

Does the media refer more to INCY or SRRK?

Summary

How does Scholar Rock compare to BioNTech?

Do insiders and institutionals believe in BNTX or SRRK?

Which has preferable valuation and earnings, BNTX or SRRK?

Do analysts rate BNTX or SRRK?

Is BNTX or SRRK more profitable?

Does the media favor BNTX or SRRK?

Which has more risk and volatility, BNTX or SRRK?

Summary

How does Scholar Rock compare to United Therapeutics?

Do analysts rate UTHR or SRRK?

Does the media prefer UTHR or SRRK?

Is UTHR or SRRK more profitable?

Do insiders and institutionals hold more shares of UTHR or SRRK?

Which has more risk & volatility, UTHR or SRRK?

Which has higher earnings and valuation, UTHR or SRRK?

Summary

How does Scholar Rock compare to Genmab A/S?

Which has more volatility and risk, GMAB or SRRK?

Which has higher valuation and earnings, GMAB or SRRK?

Does the media prefer GMAB or SRRK?

Is GMAB or SRRK more profitable?

Do institutionals & insiders hold more shares of GMAB or SRRK?

Do analysts recommend GMAB or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools